---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-24-003556"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:50:41.899942+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Entera Bio Q3 net loss $3.0M ($0.08/shr); cash $6.9M; awaits FDA SABRE ruling Jan 2025

## Summary
- Net loss of $3.0M ($0.08 basic/diluted EPS) for Q3 2024 vs $2.4M ($0.08) in Q3 2023; operating expenses $3.0M vs $2.4M.
- Cash and equivalents $6.9M; expects runway into Q3 2025.
- EB613 (oral PTH) phase 3 prep ongoing; FDA decision on SABRE regulatory endpoint expected January 2025.
- Oral GLP-1/glucagon (with OPKO) showed favorable PK/PD; plans to present at clinical conference.
- Oral GLP-2 tablet for short bowel syndrome; final PK/PD data expected H2 2024.

## SEC filing metadata
- accession: 0001178913-24-003556
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891324003556/0001178913-24-003556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891324003556/zk2432254.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-24-003556
- JSON: https://secwatch.observer/filing/0001178913-24-003556.json
- Plain text: https://secwatch.observer/filing/0001178913-24-003556.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.